China Nagano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
China Nagano has a total of 340 co-authors. Here are the top co-authors by number of shared publications:
- Kandai Nozu
Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan
20 shared publications Kandai Nozu
18 shared publications- Tomoko Horinouchi
Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
16 shared publications Tomoko Horinouchi
15 shared publications- Tomohiko Yamamura
Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
14 shared publications Shingo Ishimori
Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
13 shared publications
Latest Publications
- Open Access
- 23 September 2026
- Published by Wolters Kluwer Health in Kidney360
Symptom Burden and Clinical Clues in Gitelman Syndrome and Pseudo-Gitelman Syndrome
Background: Gitelman syndrome and pseudo-Gitelman syndrome share overlapping biochemical abnormalities, complicating clinical differentiation and genetic testing allocation. While Gitelman syndrome impairs health-related quality of life (QOL), the comparable burden in pseudo-Gitelman syndrome remains unclear. We compared QOL burden and symptom profiles between individuals with genetically confirmed Gitelman syndrome and those classified as pseudo-Gitelman syndrome. Methods: We evaluated 128 participants aged ≥10 years referred for genetic testing due to suspected Gitelman syndrome (hypokalemia and metabolic alkalosis). Participants were divided into a Gitelman syndrome subgroup (genetically confirmed biallelic SLC12A3 variants; n=66) and a pseudo-Gitelman syndrome subgroup (no disease-causing variants; n=62). Seventy controls were frequency-matched to Gitelman syndrome by age and sex. QOL and clinical manifestations were assessed using a structured 21-item questionnaire covering taste, urinary, muscle, and nonspecific symptom domains. To limit false-positive findings from multiple comparisons, P values were adjusted using the Benjamini–Hochberg procedure; the resulting adjusted P values (q values) q q = 0.33). Despite similar overall burdens, specific clinical features differed between the groups. Nocturnal enuresis scores were higher in Gitelman syndrome group than in pseudo-Gitelman syndrome group and controls (both q < 0.001); 50% of Gitelman syndrome participants reported persistence at least until elementary school entry. The taste-related domain was higher in Gitelman syndrome group than in pseudo-Gitelman syndrome group ( q = 0.01), but no individual taste item differed after correction. Conclusions: Individuals with pseudo-Gitelman syndrome experienced QOL impairment comparable to those with genetically confirmed Gitelman syndrome. However, the severity and duration of nocturnal enuresis and overall taste-related symptom burden were prominent descriptive features of Gitelman syndrome. Systematic symptom assessment may contribute to a more comprehensive clinical characterization of individuals with suspected Gitelman syndrome.
- 23 September 2026
- Published by Wolters Kluwer Health in Kidney360
Open AccessSymptom Burden and Clinical Clues in Gitelman Syndrome and Pseudo-Gitelman Syndrome
Background: Gitelman syndrome and pseudo-Gitelman syndrome share overlapping biochemical abnormalities, complicating clinical differentiation and genetic testing allocation. While Gitelman syndrome impairs health-related quality of life (QOL), the comparable burden in pseudo-Gitelman syndrome remains unclear. We compared QOL burden and symptom profiles between individuals with genetically confirmed Gitelman syndrome and those classified as pseudo-Gitelman syndrome. Methods: We evaluated 128 participants aged ≥10 years referred for genetic testing due to suspected Gitelman syndrome (hypokalemia and metabolic alkalosis). Participants were divided into a Gitelman syndrome subgroup (genetically confirmed biallelic SLC12A3 variants; n=66) and a pseudo-Gitelman syndrome subgroup (no disease-causing variants; n=62). Seventy controls were frequency-matched to Gitelman syndrome by age and sex. QOL and clinical manifestations were assessed using a structured 21-item questionnaire covering taste, urinary, muscle, and nonspecific symptom domains. To limit false-positive findings from multiple comparisons, P values were adjusted using the Benjamini–Hochberg procedure; the resulting adjusted P values (q values) q q = 0.33). Despite similar overall burdens, specific clinical features differed between the groups. Nocturnal enuresis scores were higher in Gitelman syndrome group than in pseudo-Gitelman syndrome group and controls (both q < 0.001); 50% of Gitelman syndrome participants reported persistence at least until elementary school entry. The taste-related domain was higher in Gitelman syndrome group than in pseudo-Gitelman syndrome group ( q = 0.01), but no individual taste item differed after correction. Conclusions: Individuals with pseudo-Gitelman syndrome experienced QOL impairment comparable to those with genetically confirmed Gitelman syndrome. However, the severity and duration of nocturnal enuresis and overall taste-related symptom burden were prominent descriptive features of Gitelman syndrome. Systematic symptom assessment may contribute to a more comprehensive clinical characterization of individuals with suspected Gitelman syndrome.
- Open Access
- 2 September 2026
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 19 (10)
Heterozygous COL4A3/COL4A4 variants: diagnostic trends and clinical kidney outcomes
Background: Heterozygous pathogenic variants in COL4A3 or COL4A4 are relatively common and associated with a broad clinical spectrum. However, nomenclature and risk stratification remain unsettled. We aimed to investigate temporal diagnostic trends and clinical features of haematuria-positive individuals with heterozygous COL4A3/COL4A4 variants in a genetic testing cohort. Methods: This retrospective cohort study involved 992 families genetically diagnosed with Alport syndrome at a single centre in Japan between 2006 and 2023. We identified 265 families comprising 299 haematuria-positive individuals with heterozygous pathogenic or likely pathogenic COL4A3/COL4A4 variants. For kidney failure (KF) analysis, 627 individuals, including affected relatives, were evaluated. Results: At the family level, the proportion of the study group increased from 8.4% of genetically diagnosed Alport syndrome cases during the Sanger sequencing era (2006–2015) to 26.6% during early next-generation sequencing implementation (2015–2019), and 39.1% in the recent period (2020–2023). At genetic diagnosis, 75.3% of individuals had proteinuria and 4.7% had KF. Kaplan–Meier analysis showed that the median ages at first detection of haematuria and proteinuria, and at onset of KF, were 10, 26, and 72 years, respectively. Conclusions: Individuals with haematuria and heterozygous COL4A3/COL4A4 variants accounted for an increasing proportion of genetically diagnosed cases of Alport syndrome. Although this referred cohort does not represent all individuals with heterozygous COL4A3/COL4A4 variants, our findings delineate the natural history of haematuria-positive individuals with these variants and may support early diagnosis and risk stratification aimed at preventing progression to KF.
- 2 September 2026
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 19 (10)
Open AccessHeterozygous COL4A3/COL4A4 variants: diagnostic trends and clinical kidney outcomes
Background: Heterozygous pathogenic variants in COL4A3 or COL4A4 are relatively common and associated with a broad clinical spectrum. However, nomenclature and risk stratification remain unsettled. We aimed to investigate temporal diagnostic trends and clinical features of haematuria-positive individuals with heterozygous COL4A3/COL4A4 variants in a genetic testing cohort. Methods: This retrospective cohort study involved 992 families genetically diagnosed with Alport syndrome at a single centre in Japan between 2006 and 2023. We identified 265 families comprising 299 haematuria-positive individuals with heterozygous pathogenic or likely pathogenic COL4A3/COL4A4 variants. For kidney failure (KF) analysis, 627 individuals, including affected relatives, were evaluated. Results: At the family level, the proportion of the study group increased from 8.4% of genetically diagnosed Alport syndrome cases during the Sanger sequencing era (2006–2015) to 26.6% during early next-generation sequencing implementation (2015–2019), and 39.1% in the recent period (2020–2023). At genetic diagnosis, 75.3% of individuals had proteinuria and 4.7% had KF. Kaplan–Meier analysis showed that the median ages at first detection of haematuria and proteinuria, and at onset of KF, were 10, 26, and 72 years, respectively. Conclusions: Individuals with haematuria and heterozygous COL4A3/COL4A4 variants accounted for an increasing proportion of genetically diagnosed cases of Alport syndrome. Although this referred cohort does not represent all individuals with heterozygous COL4A3/COL4A4 variants, our findings delineate the natural history of haematuria-positive individuals with these variants and may support early diagnosis and risk stratification aimed at preventing progression to KF.
- Open Access
- 27 July 2026
- Published by Elsevier in Kidney International
- Vol. 110 (4) , 1022-1028
A multi-national study examined the response sustainability to calcineurin inhibitors and long-term kidney survivals in children with genetic podocytopathies
- 27 July 2026
- Published by Elsevier in Kidney International
- Vol. 110 (4) , 1022-1028
Open AccessA multi-national study examined the response sustainability to calcineurin inhibitors and long-term kidney survivals in children with genetic podocytopathies
- Open Access
- 11 July 2026
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 30 (9) , 1341-1349
Kidney outcomes of coenzyme Q10 supplementation in patients with genetically confirmed CoQ10 nephropathy in Japan
Background: Coenzyme Q10 (CoQ10) nephropathy is a rare mitochondrial kidney disease caused by defects in CoQ10 biosynthesis and represents a unique form of steroid-resistant nephrotic syndrome with a disease-specific therapy. However, data on treatment outcomes of this disease in Japanese patients remain limited. Methods: We conducted a retrospective observational study of Japanese patients. Patients with a genetically confirmed diagnosis of CoQ10 nephropathy who received CoQ10 supplementation and had available longitudinal clinical data were included. Changes in the urinary protein-to-creatinine ratio (UPCR) and estimated glomerular filtration rate before and after treatment were evaluated, and adverse events were assessed. Results: Twelve patients were included in the analysis. The median age at treatment initiation was 9.0 years, and COQ8B was the predominant causative gene (n = 11). One patient harbored a COQ6 variant. CoQ10 supplementation was initiated at a median dose of 10.0 mg/kg/day. The median UPCR decreased from 1.66 g/gCr at baseline to 0.19 g/gCr at 12 months, and 6/7 (86%) patients with available 12-month data achieved a ≥ 50% reduction in proteinuria. Kidney function remained stable, and no patients progressed to end-stage kidney disease during a median follow-up of 28.8 months. Adverse events were mild and did not lead to treatment discontinuation. Conclusions: In Japanese patients with CoQ10 nephropathy, CoQ10 supplementation was associated with a substantial reduction in proteinuria and stabilization of kidney function. These findings indicate the importance of early genetic diagnosis and prompt initiation of targeted therapy for this treatable hereditary kidney disease.
- 11 July 2026
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 30 (9) , 1341-1349
Open AccessKidney outcomes of coenzyme Q10 supplementation in patients with genetically confirmed CoQ10 nephropathy in Japan
Background: Coenzyme Q10 (CoQ10) nephropathy is a rare mitochondrial kidney disease caused by defects in CoQ10 biosynthesis and represents a unique form of steroid-resistant nephrotic syndrome with a disease-specific therapy. However, data on treatment outcomes of this disease in Japanese patients remain limited. Methods: We conducted a retrospective observational study of Japanese patients. Patients with a genetically confirmed diagnosis of CoQ10 nephropathy who received CoQ10 supplementation and had available longitudinal clinical data were included. Changes in the urinary protein-to-creatinine ratio (UPCR) and estimated glomerular filtration rate before and after treatment were evaluated, and adverse events were assessed. Results: Twelve patients were included in the analysis. The median age at treatment initiation was 9.0 years, and COQ8B was the predominant causative gene (n = 11). One patient harbored a COQ6 variant. CoQ10 supplementation was initiated at a median dose of 10.0 mg/kg/day. The median UPCR decreased from 1.66 g/gCr at baseline to 0.19 g/gCr at 12 months, and 6/7 (86%) patients with available 12-month data achieved a ≥ 50% reduction in proteinuria. Kidney function remained stable, and no patients progressed to end-stage kidney disease during a median follow-up of 28.8 months. Adverse events were mild and did not lead to treatment discontinuation. Conclusions: In Japanese patients with CoQ10 nephropathy, CoQ10 supplementation was associated with a substantial reduction in proteinuria and stabilization of kidney function. These findings indicate the importance of early genetic diagnosis and prompt initiation of targeted therapy for this treatable hereditary kidney disease.
- 30 May 2026
- Published by Springer Nature in CEN Case Reports
- Vol. 15 (3)
A deep intronic IFT172 variant causing pseudoexon inclusion identified by whole-genome sequencing in nephronophthisis
Nephronophthisis is an autosomal recessive ciliopathy and a major genetic cause of end-stage kidney disease in children and young adults. Although next-generation sequencing panels have improved diagnostic yield, some patients remain genetically unresolved, partly due to deep intronic variants that disrupt pre-mRNA splicing and are not captured by exon-focused approaches. We report a 13-year-old boy who presented with advanced kidney dysfunction, small renal cysts, and kidney histopathology consistent with nephronophthisis. Targeted gene panel sequencing failed to identify causative pathogenic variants beyond a missense variant of uncertain significance. Whole-genome sequencing subsequently revealed compound heterozygous variants in IFT172 (NM_015662.3): a missense variant (c.4696C > T, p.Arg1566Cys) and a deep intronic variant (c.4915-94A > G). In silico analysis predicted activation of cryptic splice sites leading to inclusion of an 86-bp pseudoexon, which was confirmed by a minigene splicing assay. These findings established a molecular diagnosis of IFT172-related nephronophthisis. To our knowledge, this is the first report demonstrating pseudoexon inclusion in IFT172, thereby expanding its mutational spectrum. Our case underscores the importance of evaluating deep intronic regions using whole-genome sequencing and functional validation in genetically unresolved nephronophthisis.
- 30 May 2026
- Published by Springer Nature in CEN Case Reports
- Vol. 15 (3)
A deep intronic IFT172 variant causing pseudoexon inclusion identified by whole-genome sequencing in nephronophthisis
Nephronophthisis is an autosomal recessive ciliopathy and a major genetic cause of end-stage kidney disease in children and young adults. Although next-generation sequencing panels have improved diagnostic yield, some patients remain genetically unresolved, partly due to deep intronic variants that disrupt pre-mRNA splicing and are not captured by exon-focused approaches. We report a 13-year-old boy who presented with advanced kidney dysfunction, small renal cysts, and kidney histopathology consistent with nephronophthisis. Targeted gene panel sequencing failed to identify causative pathogenic variants beyond a missense variant of uncertain significance. Whole-genome sequencing subsequently revealed compound heterozygous variants in IFT172 (NM_015662.3): a missense variant (c.4696C > T, p.Arg1566Cys) and a deep intronic variant (c.4915-94A > G). In silico analysis predicted activation of cryptic splice sites leading to inclusion of an 86-bp pseudoexon, which was confirmed by a minigene splicing assay. These findings established a molecular diagnosis of IFT172-related nephronophthisis. To our knowledge, this is the first report demonstrating pseudoexon inclusion in IFT172, thereby expanding its mutational spectrum. Our case underscores the importance of evaluating deep intronic regions using whole-genome sequencing and functional validation in genetically unresolved nephronophthisis.
- 26 May 2026
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 30 (9) , 1-8
Clinical and functional evaluation of non-missense MYH9 variants in MYH9-related disease
Background MYH9-related disease (MYH9-RD) is an autosomal dominant disorder characterized by thrombocytopenia, giant platelets, and variable systemic manifestations including nephropathy. While most pathogenic MYH9 variants are missense substitutions causing dominant-negative effects, the pathogenic potential of non-missense variants, particularly those affecting splicing, remains unclear. Methods MYH9 (NM_002473.6) variants registered as “DM” (disease-causing variant) or “DM?” (possible disease-causing variant) in HGMD® were curated. After excluding missense and non-analyzable variants, ten intronic or single-base deletions were selected. Splicing effects were assessed by minigene assays in HEK293T cells and compared with SpliceAI predictions. Clinical information was reviewed. Results Aberrant splicing was confirmed in three variants: c.3838-2A>G, c.5765+2T>A, and c.5765+2T>G. The c.3838-2A>G variant caused in-frame skipping of exon 29, non-truncating variant, whereas the latter two induced inclusion of a cryptic 50-bp exon with premature termination codons in the final exon that can escape nonsense-mediated decay. These spliceogenic variants were associated with MYH9-RD phenotypes producing abnormal proteins that likely exert dominant-negative effects. The remaining seven variants showed no splicing abnormalities and were reported in non-MYH9-RD contexts, suggesting limited evidence for pathogenicity. SpliceAI predictions were concordant with experimental results. Conclusions This study provides systematic evidence that some aberrant splicing MYH9 variants can lead to MYH9-RD with dominant-negative pathogenesis. Conversely, several variants previously annotated as “DM?” showed no functional or clinical relevance, arguing against a pathogenic role and supporting their consideration as likely benign or uncertain significance. Integrating in silico prediction with experimental validation improves variant interpretation and has implications for the clinical management of MYH9-RD.
- 26 May 2026
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 30 (9) , 1-8
Clinical and functional evaluation of non-missense MYH9 variants in MYH9-related disease
Background MYH9-related disease (MYH9-RD) is an autosomal dominant disorder characterized by thrombocytopenia, giant platelets, and variable systemic manifestations including nephropathy. While most pathogenic MYH9 variants are missense substitutions causing dominant-negative effects, the pathogenic potential of non-missense variants, particularly those affecting splicing, remains unclear. Methods MYH9 (NM_002473.6) variants registered as “DM” (disease-causing variant) or “DM?” (possible disease-causing variant) in HGMD® were curated. After excluding missense and non-analyzable variants, ten intronic or single-base deletions were selected. Splicing effects were assessed by minigene assays in HEK293T cells and compared with SpliceAI predictions. Clinical information was reviewed. Results Aberrant splicing was confirmed in three variants: c.3838-2A>G, c.5765+2T>A, and c.5765+2T>G. The c.3838-2A>G variant caused in-frame skipping of exon 29, non-truncating variant, whereas the latter two induced inclusion of a cryptic 50-bp exon with premature termination codons in the final exon that can escape nonsense-mediated decay. These spliceogenic variants were associated with MYH9-RD phenotypes producing abnormal proteins that likely exert dominant-negative effects. The remaining seven variants showed no splicing abnormalities and were reported in non-MYH9-RD contexts, suggesting limited evidence for pathogenicity. SpliceAI predictions were concordant with experimental results. Conclusions This study provides systematic evidence that some aberrant splicing MYH9 variants can lead to MYH9-RD with dominant-negative pathogenesis. Conversely, several variants previously annotated as “DM?” showed no functional or clinical relevance, arguing against a pathogenic role and supporting their consideration as likely benign or uncertain significance. Integrating in silico prediction with experimental validation improves variant interpretation and has implications for the clinical management of MYH9-RD.
- Open Access
- 8 April 2026
- Published by Springer Nature in Research Square
A population-scale map of structural variation in the Japanese population
Structural variants (SVs) are major contributors to the genetic variation underlying human traits and diseases, and they frequently exhibit population-specific patterns. However, previous studies have provided limited coverage of diverse ancestries. Here, using the 1000 Genomes Project data as a population reference, we characterized SVs in Japanese individuals and assessed their potential disease associations. We identified 144,978 SVs, of which 26.8% (38,742 SVs) were novel. SV-based analyses stratified Japanese individuals in the context of global populations and revealed population substructure within Japan, distinguishing the central Hondo cluster from the smaller Ryukyu cluster. We also identified SVs affecting clinically relevant loci. By integrating SVs with single-nucleotide variants, we constructed a Japanese population-specific imputation panel and subsequently identified associations between SVs in the human leukocyte antigen region and primary biliary cholangitis, hepatitis B infection, and steroid-sensitive nephrotic syndrome. These findings advance our understanding of SVs in the Japanese population and provide a baseline resource for future genomic studies of SVs in Japan.
- 8 April 2026
- Published by Springer Nature in Research Square
Open AccessA population-scale map of structural variation in the Japanese population
Structural variants (SVs) are major contributors to the genetic variation underlying human traits and diseases, and they frequently exhibit population-specific patterns. However, previous studies have provided limited coverage of diverse ancestries. Here, using the 1000 Genomes Project data as a population reference, we characterized SVs in Japanese individuals and assessed their potential disease associations. We identified 144,978 SVs, of which 26.8% (38,742 SVs) were novel. SV-based analyses stratified Japanese individuals in the context of global populations and revealed population substructure within Japan, distinguishing the central Hondo cluster from the smaller Ryukyu cluster. We also identified SVs affecting clinically relevant loci. By integrating SVs with single-nucleotide variants, we constructed a Japanese population-specific imputation panel and subsequently identified associations between SVs in the human leukocyte antigen region and primary biliary cholangitis, hepatitis B infection, and steroid-sensitive nephrotic syndrome. These findings advance our understanding of SVs in the Japanese population and provide a baseline resource for future genomic studies of SVs in Japan.
- 3 January 2026
- Published by Springer Nature in CEN Case Reports
- Vol. 15 (1) , 8
Whole-genome sequencing identified a deep intronic COL4A5 variant causing aberrant splicing in a female patient with X-linked Alport syndrome
Alport syndrome is an inherited kidney disease caused by pathogenic variants in COL4A3, COL4A4, or COL4A5, encoding type IV collagen chains of the glomerular basement membrane. Genetic confirmation is essential for its diagnosis, prognosis, and donor selection; however, conventional sequencing may fail to detect pathogenic variants, leaving a subset of clinically suspected patients without a genetic diagnosis. We report a 16-year-old girl with persistent hematuria and proteinuria, initially diagnosed with Alport syndrome at 2 years of age based on kidney biopsy findings of a basket-weave glomerular basement membrane and mosaic α5(IV) staining. Despite a family history compatible with this diagnosis, targeted exome sequencing at 8 years of age did not identify pathogenic variants. Whole-genome sequencing at 16 years revealed a deep intronic variant in COL4A5 (NM_000495.5) (c.276 + 1306G > A). In silico analysis with SpliceAI predicted the creation of de novo acceptor and donor splice sites, leading to the inclusion of a 103-bp cryptic exon within intron 4. A minigene assay confirmed aberrant splicing and demonstrated that the inserted exon resulted in a frameshift and premature stop codon (p.Gly93Phefs*99). This case highlights the diagnostic utility of whole-genome sequencing in combination with splicing prediction and functional validation to resolve suspected cases of Alport syndrome in which the genetic cause has remained unclear. As sequencing technologies advance, such integrative approaches may become increasingly important in clinical practice, thereby improving diagnostic yield and supporting the development of RNA-based therapies.
- 3 January 2026
- Published by Springer Nature in CEN Case Reports
- Vol. 15 (1) , 8
Whole-genome sequencing identified a deep intronic COL4A5 variant causing aberrant splicing in a female patient with X-linked Alport syndrome
Alport syndrome is an inherited kidney disease caused by pathogenic variants in COL4A3, COL4A4, or COL4A5, encoding type IV collagen chains of the glomerular basement membrane. Genetic confirmation is essential for its diagnosis, prognosis, and donor selection; however, conventional sequencing may fail to detect pathogenic variants, leaving a subset of clinically suspected patients without a genetic diagnosis. We report a 16-year-old girl with persistent hematuria and proteinuria, initially diagnosed with Alport syndrome at 2 years of age based on kidney biopsy findings of a basket-weave glomerular basement membrane and mosaic α5(IV) staining. Despite a family history compatible with this diagnosis, targeted exome sequencing at 8 years of age did not identify pathogenic variants. Whole-genome sequencing at 16 years revealed a deep intronic variant in COL4A5 (NM_000495.5) (c.276 + 1306G > A). In silico analysis with SpliceAI predicted the creation of de novo acceptor and donor splice sites, leading to the inclusion of a 103-bp cryptic exon within intron 4. A minigene assay confirmed aberrant splicing and demonstrated that the inserted exon resulted in a frameshift and premature stop codon (p.Gly93Phefs*99). This case highlights the diagnostic utility of whole-genome sequencing in combination with splicing prediction and functional validation to resolve suspected cases of Alport syndrome in which the genetic cause has remained unclear. As sequencing technologies advance, such integrative approaches may become increasingly important in clinical practice, thereby improving diagnostic yield and supporting the development of RNA-based therapies.
- Open Access
- 1 January 2026
- Published by Japanese Society for Pediatric Nephrology in Japanese journal of pediatric nephrology
- Vol. 39, rv.26-008
Genetic Testing in Kidney Diseases: A Practical Approach for Beginners
近年,次世代シークエンサーの発展により,遺伝性腎疾患の診断は大きく進歩した.遺伝学的検査は疾患の確定診断に加え,治療方針の決定,予後予測,合併症のサーベイランス,家族への遺伝カウンセリングなど,診療全体に重要な役割を果たしている.一方で,適切な検査の選択や結果の解釈には,遺伝性疾患を疑う視点や検査の特徴・限界を理解することが不可欠である.本稿では,腎疾患診療に携わる初学者を対象に,遺伝学的検査を考慮すべき患者の特徴,現在臨床で用いられる主な検査法,バリアント解釈におけるin silico解析の活用と留意点,さらに全ゲノム解析などの新たな解析技術について概説した.遺伝学的検査は臨床診断を置き換えるものではなく,患者の臨床像と統合して活用することで最大限の価値を発揮する.本稿が日常診療における遺伝学的検査の理解と適切な活用の一助となることを期待する.
- 1 January 2026
- Published by Japanese Society for Pediatric Nephrology in Japanese journal of pediatric nephrology
- Vol. 39, rv.26-008
Open AccessGenetic Testing in Kidney Diseases: A Practical Approach for Beginners
近年,次世代シークエンサーの発展により,遺伝性腎疾患の診断は大きく進歩した.遺伝学的検査は疾患の確定診断に加え,治療方針の決定,予後予測,合併症のサーベイランス,家族への遺伝カウンセリングなど,診療全体に重要な役割を果たしている.一方で,適切な検査の選択や結果の解釈には,遺伝性疾患を疑う視点や検査の特徴・限界を理解することが不可欠である.本稿では,腎疾患診療に携わる初学者を対象に,遺伝学的検査を考慮すべき患者の特徴,現在臨床で用いられる主な検査法,バリアント解釈におけるin silico解析の活用と留意点,さらに全ゲノム解析などの新たな解析技術について概説した.遺伝学的検査は臨床診断を置き換えるものではなく,患者の臨床像と統合して活用することで最大限の価値を発揮する.本稿が日常診療における遺伝学的検査の理解と適切な活用の一助となることを期待する.
- Open Access
- 27 October 2025
- Published by SAGE Publications in Biomarker Insights
- Vol. 20
Latent Intrarenal Renin-Angiotensin-Aldosterone System Activation Could Persist Until Early School-Aged in Children with a History of Low Birth Weight
Background: The renin-angiotensin-aldosterone system (RAAS) plays a crucial role in kidney development and the progression of chronic kidney disease (CKD). Objectives: To identify children with low birth weight (LBW) at risk of CKD who have RAAS activation. Design: We conducted a prospective cohort study to evaluate whether a history of LBW contributes to the development of latent RAAS activation using urine samples from patients with short stature with no clinical kidney symptoms. Additionally, among children who had idiopathic nephrotic syndrome (INS), we examined how a history of LBW contributes to the development of latent RAAS activation using residual kidney biopsy samples. Methods: We prospectively evaluated angiotensinogen (AGT) using spot urine in children with and without a history of LBW, who required evaluation for short stature without kidney symptoms at registration. We also performed immunohistochemical staining of AGT using kidney biopsy specimens of subjects with and without a history of LBW who had INS. Urinary AGT was assessed as a marker of intrarenal RAAS. Results: In 45 children (median age 5 years), urinary AGT/creatinine (Cr) levels were significantly higher in children with a history of LBW (n = 24) than in those without (n = 21, median: 12.6 vs 6.7 µg/g・Cr, mean: 15.4 vs 9.1 µg/g・Cr, P < .01). The unadjusted mean difference between the 2 groups and the 95% confidence interval were 6.3 and (1.6, 11.1), respectively. In the immunohistochemical kidney pathological study, the positive area of AGT staining in the kidney tubules of 3 subjects with a history of LBW was more extensive than that of 3 additional subjects without a history of LBW. Conclusion: Our results indicated that latent intrarenal RAAS activation in children with a history of LBW persists until early school age and may contribute to the progression of CKD.
- 27 October 2025
- Published by SAGE Publications in Biomarker Insights
- Vol. 20
Open AccessLatent Intrarenal Renin-Angiotensin-Aldosterone System Activation Could Persist Until Early School-Aged in Children with a History of Low Birth Weight
Background: The renin-angiotensin-aldosterone system (RAAS) plays a crucial role in kidney development and the progression of chronic kidney disease (CKD). Objectives: To identify children with low birth weight (LBW) at risk of CKD who have RAAS activation. Design: We conducted a prospective cohort study to evaluate whether a history of LBW contributes to the development of latent RAAS activation using urine samples from patients with short stature with no clinical kidney symptoms. Additionally, among children who had idiopathic nephrotic syndrome (INS), we examined how a history of LBW contributes to the development of latent RAAS activation using residual kidney biopsy samples. Methods: We prospectively evaluated angiotensinogen (AGT) using spot urine in children with and without a history of LBW, who required evaluation for short stature without kidney symptoms at registration. We also performed immunohistochemical staining of AGT using kidney biopsy specimens of subjects with and without a history of LBW who had INS. Urinary AGT was assessed as a marker of intrarenal RAAS. Results: In 45 children (median age 5 years), urinary AGT/creatinine (Cr) levels were significantly higher in children with a history of LBW (n = 24) than in those without (n = 21, median: 12.6 vs 6.7 µg/g・Cr, mean: 15.4 vs 9.1 µg/g・Cr, P < .01). The unadjusted mean difference between the 2 groups and the 95% confidence interval were 6.3 and (1.6, 11.1), respectively. In the immunohistochemical kidney pathological study, the positive area of AGT staining in the kidney tubules of 3 subjects with a history of LBW was more extensive than that of 3 additional subjects without a history of LBW. Conclusion: Our results indicated that latent intrarenal RAAS activation in children with a history of LBW persists until early school age and may contribute to the progression of CKD.